Sterling Capital Management’s Definium Therapeutics DFTX Stock Holding History

Sterling Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.2K	Sell	2,443 -1,472	-38%	-$25K	﹤0.01%	1673
2025 Q4	$52.4K	Buy	3,915 +284	+8%	+$3.52K	﹤0.01%	1785
2025 Q3	$42.8K	Buy	3,631 +2,175	+149%	+$20.3K	﹤0.01%	1805
2025 Q2	$9.45K	Buy	1,456 +1,369	+1,574%	+$9K	﹤0.01%	2167
2025 Q1	$509	Buy	87 +13	+18%	+$93	﹤0.01%	2953
2024 Q4	$515	Hold	74	–	–	﹤0.01%	3030
2024 Q3	$421	Buy	+74	New	+$515	﹤0.01%	2936

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sterling Capital Management's DFTX Position: Q1 2026 in Review

Sterling Capital Management reduced its Definium Therapeutics (DFTX) stake by 38% in Q1 2026, selling an estimated $25K and leaving 2,443 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Sterling Capital Management first reported a position in DFTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $52.4K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Sterling Capital Management held 2,443 shares of Definium Therapeutics worth $46.2K as of Q1 2026.
Sterling Capital Management sold 1,472 Definium Therapeutics shares in Q1 2026, an estimated $25K.
Definium Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1673 holding.
Sterling Capital Management first reported a position in Definium Therapeutics in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Definium Therapeutics position peaked at $52.4K in Q4 2025.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.